Immix Biopharma, Inc. (IMMX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Immix Biopharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Immix Biopharma, Inc. (IMMX) has returned 74.19% so far this year and 442.26% over the past 12 months.

Based on dividend-adjusted daily data since Dec 16, 2021, IMMX's average daily return is +0.32%, while the average monthly return is +5.52%. At this rate, your investment would double in approximately 1.1 years.

Historically, 50% of months were positive and 50% were negative. The best month was Dec 2022 with a return of +89.3%, while the worst month was Jan 2024 at -44.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, IMMX closed higher 45% of trading days. The best single day was Jan 3, 2022 with a return of +62.4%, while the worst single day was Apr 5, 2022 at -22.0%.

Immix Biopharma, Inc. has an annualized alpha of 99.65%, beta of 1.10, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since December 17, 2021.

• This stock captured 43.10% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -62.42%) — a profile typical of hedging or uncorrelated assets.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IMMX ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Immix Biopharma, Inc. (IMMX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Immix Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immix Biopharma, Inc. was 88.89%, occurring on Nov 10, 2022. Recovery took 275 trading sessions.

The current Immix Biopharma, Inc. drawdown is 18.08%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Immix Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Immix Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.